RBC Capital Maintains Outperform on Spruce Biosciences, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Spruce Biosciences (NASDAQ:SPRB) and increased the price target from $8 to $9.

February 26, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Spruce Biosciences and raised the price target from $8 to $9.
The maintenance of an Outperform rating combined with an increased price target by a reputable analyst like Gregory Renza suggests a positive outlook on SPRB's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100